ArticleJournal of the American Heart Association2024
Use of Technetium-99m-Pyrophosphate Single-Photon Emission Computed Tomography/Computed Tomography in Monitoring Therapeutic Changes of Eplontersen in Patients With Hereditary Transthyretin Amyloid Cardiomyopathy.
Article in Journal of the American Heart Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Long-Term Impact of Eplontersen on Technetium-99m-Pyrophosphate Single-Photon Emission Computed Tomography/Computed Tomography in Ala97Ser Hereditary Transthyretin Amyloid Cardiomyopathy.Acta Cardiologica Sinica · 2026Article
- Therapeutic Efficacy and Safety Profile of Eplontersen in Hereditary Transthyretin-Mediated Amyloidosis: A Systematic Review.Health science reports · 2026Review
- Artificial intelligence-driven longitudinal quantification of technetium pyrophosphate uptake in cardiac amyloidosis: Correlation with multimodality imaging and outcomes.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2026Article
- QuantitativeAsia Oceania journal of nuclear medicine & biology · 2026Article
- Effects of tafamidis on serial [European journal of nuclear medicine and molecular imaging · 2025Article
- Etiological Treatment of Cardiac Amyloidosis: Standard of Care and Future Directions.Current heart failure reports · 2025Review
- Impact of Tafamidis on [European journal of nuclear medicine and molecular imaging · 2025Article
- 2025 Update Consensus ofActa Cardiologica Sinica · 2025Article
- Nuclear Medicine Imaging for the Diagnosis of ATTR Cardiac Amyloidosis: Report of Japanese Society of Nuclear Cardiology Working Group.Annals of nuclear cardiology · 2025Review
- From Molecular to Radionuclide and Pharmacological Aspects in Transthyretin Cardiac Amyloidosis.International journal of molecular sciences · 2024Review
- In Vivo Cardiovascular Molecular Imaging: Contributions to Precision Medicine and Drug Development.Circulation · 2024Review
- Novel Insights into Non-Invasive Diagnostic Techniques for Cardiac Amyloidosis: A Critical Review.Diagnostics (Basel, Switzerland) · 2024Review
- Review
- A review of Eplontersen use in hereditary transthyretin amyloidosis.Neurodegenerative disease managementReview
- Diagnosis of ATTR cardiac amyloidosis byArchivos peruanos de cardiologia y cirugia cardiovascularReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHereditary transthyretin amyloid cardiomyopathy (hATTR-CM) is a progressive and fatal disease. Recent evidence indicates that bone scintigraphy may serve as a tool to monitor the effectiveness of hATTR-CM treatment. The objective of this study was to examine how eplontersen therapy influences the semiquantitative uptake of technetium-99m-pyrophosphate in individuals diagnosed with hATTR-CM. METHODS AND
resultsWe retrospectively analyzed a prospective cohort from the NEURO-TTRansform trial, including patients with hATTR-CM receiving eplontersen (45 mg/4 weeks). A control group comprised patients with hATTR-CM who had not received eplontersen, inotersen, tafamidis, or patisiran. Technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography was conducted at baseline and during follow-up. Thirteen patients with hATTR-CM were enrolled, with 6 receiving eplontersen and 7 serving as the control group. The median follow-up time was 544 days. The eplontersen group exhibited a significant decrease in volumetric heart and lung ratio (3.774 to 2.979,
conclusionsThe volumetric heart and lung ratio used to quantify technetium-99m-pyrophosphate uptake showed a significant reduction subsequent to eplontersen treatment in individuals diagnosed with hATTR-CM. These findings suggest the potential efficacy of eplontersen in treating hATTR-CM and highlight the value of technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography as a tool for monitoring therapeutic effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.